Two susceptibility loci identified for prostate cancer aggressiveness

Nature Communications

Volumn 6, Issue , 2015, Pages

  Berndt, Sonja I ^a   Wang, Zhaoming ^a,b   Yeager, Meredith ^a,b   Alavanja, Michael C ^a   Albanes, Demetrius ^a   Amundadottir, Laufey ^a   Andriole, Gerald ^c   Beane Freeman, Laura ^a   Campa, Daniele ^d   Cancel Tassin, Geraldine ^e   Canzian, Federico ^d   Cornu, Jean Nicolas ^a   Cussenot, Olivier ^e   Diver, W Ryan ^f   Gapstur, Susan M ^f   Grönberg, Henrik ^g   Haiman, Christopher A ^h   Henderson, Brian ^h   Hutchinson, Amy ^b   Hunter, David J ⁱ   Key, Timothy J ^j   Kolb, Suzanne ^k   Koutros, Stella ^a   Kraft, Peter ⁱ   Le Marchand, Loic ^l   Lindström, Sara ⁱ   Machiela, Mitchell J ^a   Ostrander, Elaine A ^m   Riboli, Elio ⁿ   Schumacher, Fred ^h   Siddiq, Afshan ⁿ   Stanford, Janet L ^k,o   Stevens, Victoria L ^f   Travis, Ruth C ^j   Tsilidis, Konstantinos K ^p   Virtamo, Jarmo ^q   Weinstein, Stephanie ^a   Wilkund, Fredrik ^g   Xu, Jianfeng ^r   Lilly Zheng, S ^r   Yu, Kai ^a   Wheeler, William ^s   Zhang, Han ^a   Sampson, Joshua ^a   Black, Amanda ^a   Jacobs, Kevin ^a   Hoover, Robert N ^a   Tucker, Margaret ^a   Chanock, Stephen J ^a   Ingles, Sue A ^h   Kittles, Rick A ^t   Strom, Sara S ^u   Rybicki, Benjamin A ^v   Nemesure, Barbara ^w   Isaacs, William B ^x   Zheng, Wei ^y   Pettaway, Curtis A ^u   Yeboah, Edward D ^z,aa   Tettey, Yao ^z,aa   Biritwum, Richard B ^z,aa   Adjei, Andrew A ^z,aa   Tay, Evelyn ^z,aa   Truelove, Ann ^ab   Niwa, Shelley ^ab   Chokkalingam, Anand P ^ac   John, Esther M ^ad,ae   Murphy, Adam B ^af   Signorello, Lisa B ^i,ag   Carpten, John ^ah   Leske, M Cristina ^w   Wu, Suh Yuh ^w   Hennis, Anslem J M ^w,ai   Neslund Dudas, Christine ^v   Hsing, Ann W ^ad,ae   Chu, Lisa ^ad,ae   Goodman, Phyllis J ^k   Klein, Eric A ^aj   Witte, John S ^ak,al   Casey, Graham ^h   Kaggwa, Sam ^am   Cook, Michael B ^a   Stram, Daniel O ^h   Blot, William J ^y,ag   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f AMERICAN CANCER SOCIETY   (United States)

^g KAROLINSKA INSTITUTE   (Sweden)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k Fred Hutchinson Cancer Research Center   (United States)

^l UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^m NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

ⁿ IMPERIAL COLLEGE LONDON   (United Kingdom)

^o UNIVERSITY OF WASHINGTON   (United States)

^p UNIVERSITY OF IOANNINA   (Greece)

^q NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^r WAKE FOREST SCHOOL OF MEDICINE   (United States)

^s INFORMATION MANAGEMENT SERVICES INC   (United States)

^t UNIVERSITY OF ARIZONA   (United States)

^u UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^v HENRY FORD HOSPITAL   (United States)

^w STONY BROOK UNIVERSITY   (United States)

^x JOHNS HOPKINS HOSPITAL   (United States)

^y VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^z KORLE BU TEACHING HOSPITAL   (Ghana)

^aa UNIVERSITY OF GHANA   (Ghana)

^ab WESTAT   (United States)

^ac UNIVERSITY OF CALIFORNIA   (United States)

^ad CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^ae STANFORD CANCER INSTITUTE   (United States)

^af NORTHWESTERN UNIVERSITY   (United States)

^ag INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^ah TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^ai UNIVERSITY OF THE WEST INDIES   (Jamaica)

^aj LERNER RESEARCH INSTITUTE   (United States)

^ak UNIVERSITY OF CALIFORNIA   (United States)

^al UNIVERSITY OF CALIFORNIA   (United States)

^am MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; GENETIC ANALYSIS; MENS HEALTH;

ARTICLE; CHROMOSOME 5Q; CONTROLLED STUDY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAALADL2 GENE; ONCOGENE; PROSTATE CANCER; RASA1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; CANCER GRADING; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; PROSTATE TUMOR; TUMOR INVASION;

CASE-CONTROL STUDIES; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS;

EID: 84929000290     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7889     Document Type: Article

References (66)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
2. Lindstrom, L. S. et al. Familial concordance in cancer survival: a Swedish population-based study. Lancet Oncol. 8, 1001-1006 (2007).
3. Hemminki, K. Familial risk and familial survival in prostate cancer. World J. Urol. 30, 143-148 (2012).
4. Gleason, D. F. Histologic grading of prostate cancer: a perspective. Hum. Pathol. 23, 273-279 (1992).
5. Witte, J. S. et al. Genomewide scan for prostate cancer-Aggressiveness loci. Am. J. Hum. Genet. 67, 92-99 (2000).
6. Witte, J. S. et al. Genome-wide scan of brothers: replication and fine mapping of prostate cancer susceptibility and aggressiveness loci. Prostate 57, 298-308 (2003).
7. Slager, S. L. et al. Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate 66, 173-179 (2006).
8. Schaid, D. J. et al. Genome-wide linkage scan of prostate cancer Gleason score and confirmation of chromosome 19q. Hum. Genet. 121, 729-735 (2007).
9. Sun, J. et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res. 69, 10-15 (2009).
10. Xu, J. et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc. Natl Acad. Sci. USA 107, 2136-2140 (2010).
11. Al Olama, A. A. et al. A meta-Analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and nonaggressive disease. Hum. Mol. Genet. 22, 408-415 (2013).
12. Schumacher, F. R. et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum. Mol. Genet. 20, 3867-3875 (2011).
13. Yeager, M. et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39, 645-649 (2007).
14. Gudmundsson, J. et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39, 631-637 (2007).
15. Gudmundsson, J. et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 39, 977-983 (2007).
16. Thomas, G. et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40, 310-315 (2008).
17. Gudmundsson, J. et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet. 40, 281-283 (2008).
18. Eeles, R. A. et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316-321 (2008).
19. Gudmundsson, J. et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet. 41, 1122-1126 (2009).
20. Eeles, R. A. et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 41, 1116-1121 (2009).
21. Takata, R. et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat. Genet. 42, 751-754 (2010).
22. Haiman, C. A. et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat. Genet. 43, 570-573 (2011).
23. Kote-Jarai, Z. et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat. Genet. 43, 785-791 (2011).
24. Xu, J. et al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat. Genet. 44, 1231-1235 (2012).
25. Eeles, R. A. et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat. Genet. 45, 385-391 (2013).
26. Al Olama, A. A. et al. A meta-Analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat. Genet. 46, 1103-1109 (2014).
27. Wu, M. C. et al. Rare-variant association testing for sequencing data with the sequence kernel association test. Am. J. Hum. Genet. 89, 82-93 (2011).
28. Abecasis, G. R. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56-65 (2012).
29. Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS. Genet. 5, e1000529 (2009).
30. Lindstrom, S. et al. Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers-results from BPC3. PLoS ONE 6, e17142 (2011).
31. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580-585 (2013).
32. Grundberg, E. et al. Mapping cis-And trans-regulatory effects across multiple tissues in twins. Nat. Genet. 44, 1084-1089 (2012).
33. Grundberg, E. et al. Global analysis of DNA methylation variation in adipose tissue from twins reveals links to disease-Associated variants in distal regulatory elements. Am. J. Hum. Genet. 93, 876-890 (2013).
34. Luedeke, M. et al. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes. Cancer Epidemiol. Biomarkers Prev. 18, 3030-3035 (2009).
35. McCormick, F. ras GTPase activating protein: signal transmitter and signal terminator. Cell 56, 5-8 (1989).
36. Henkemeyer, M. et al. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-Activating protein. Nature 377, 695-701 (1995).
37. Eerola, I. et al. Capillary malformation-Arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am. J. Hum. Genet. 73, 1240-1249 (2003).
38. Burrows, P. E. et al. Lymphatic abnormalities are associated with RASA1 gene mutations in mouse and man. Proc. Natl Acad. Sci. USA 110, 8621-8626 (2013).
39. Lolli, G. & Johnson, L. N. CAK-cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle 4, 572-577 (2005).
40. Karan, D., Kelly, D. L., Rizzino, A., Lin, M. F. & Batra, S. K. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 23, 967-975 (2002).
41. Romanuik, T. L. et al. LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med. Genomics 3, 43 (2010).
42. Ristau, B. T., O'Keefe, D. S. & Bacich, D. J. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol. Oncol. 32, 272-279 (2013).
43. Whitaker, H. C. et al. N-Acetyl-L-Aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype. Oncogene 33, 5274-5287 (2013).
44. Burgner, D. et al. A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genet. 5, e1000319 (2009).
45. Wang, X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 14, 1012-1017 (2008).
46. Wang, X. & El Naqa, I. M. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics 24, 325-332 (2008).
47. FitzGerald, L. M. et al. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol. Biomarkers Prev. 20, 1196-1203 (2011).
48. Parikh, H. et al. Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. Hum. Genet. 129, 675-685 (2011).
49. Kote-Jarai, Z. et al. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum. Genet. 129, 687-694 (2011).
50. Bensen, J. T. et al. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. Prostate 73, 11-22 (2013).
51. Schaid, D. J. et al. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum. Genet. 120, 471-485 (2006).
52. Machiela, M. J. et al. Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium. Am. J. Epidemiol. 176, 1121-1129 (2012).
53. Gilliland, F. D. et al. Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993. J. Urol. 165, 846-850 (2001).
54. Allsbrook, Jr. W. C. et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum. Pathol. 32, 74-80 (2001).
55. Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310-1319 (2009).
56. Hayes, R. B. et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin. Trials 21, 349S-355S (2000).
57. Yu, K. et al. Population substructure and control selection in genome-wide association studies. PLoS ONE 3, e2551 (2008).
58. Pritchard, J. K., Stephens, M. & Donnelly, P. Inference of population structure using multilocus genotype data. Genetics 155, 945-959 (2000).
59. Wang, Z. et al. Improved imputation of common and uncommon SNPs with a new reference set. Nat. Genet. 44, 6-7 (2012).
60. The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann. Epidemiol. 4, 1-10 (1994).
61. Calle, E. E. et al. The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 94, 2490-2501 (2002).
62. Giovannucci, E. et al. A prospective study of dietary fat and risk of prostate cancer. J. Natl Cancer Inst. 85, 1571-1579 (1993).
63. Alavanja, M. C. et al. The Agricultural Health Study. Environ. Health Perspect. 104, 362-369 (1996).
64. Kolonel, L. N. et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am. J. Epidemiol. 151, 346-357 (2000).
65. Riboli, E. et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 5, 1113-1124 (2002).
66. Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 40, D930-D934 (2012).